MarketScreener

Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma

(NYSE: PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO ® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who ...

Real-world results confirm benefit of antigen therapy for prostate cancer

Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with ...
jen.jiji

Drugs: bladder cancer, EU green light for pembrolizumab plus enfortumab vedotin before and after surgery (2)

In the study, pembrolizumab plus enfortumab vedotin as perioperative treatment demonstrated a statistically significant improvement in event-free survival (Efs), reducing the risk of Efs events by 47% ...
jen.jiji

Bladder cancer, EU green light for pembrolizumab plus enfortumab vedotin before and after surgery

Msd announced today that the European Commission has approved pembrolizumab in combination with enfortumab vedotin, as neoadjuvant treatment and subsequently, after radical cystectomy, as adjuvant ...